After the FDA rejection of Zurzuvae in one type of depression and the triple failure of neuro asset dalzanemdor, Sage was ...

Inhibiting an overabundant enzyme saved a key component of a brain signaling pathway that is vital for motor control in a ...

Biogen has commenced dosing in the Phase III BRAVE study to assess omaveloxolone in children of two to less than 16 years of age with Friedreich ataxia (FA). The trial aims to assess the safety, ...

Boston Globe via Getty Images Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics represents a strategic move into cardiovascular genetic medicine.

Company News Published 06/18/2025, 07:35 AM 0 Biogen initiates phase 3 trial of omaveloxolone for children with FA BIIB -0.24% ...

Review quarterly and annual revenue, net income, and cash flow for Stoke Therapeutics Inc (0GT:XMUN) stock through the last fiscal year.

Most notably, it acquired Scorpion Therapeutics and its PI3Kα inhibitor program for $2.5 billion in January. The deal for Verve is expected to close in the third quarter.

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary TANGO (Targeted ...

GLP-1 therapeutics are gaining popularity beyond diabetes due to their surprising efficacy in weight management and emerging potential in a broad range of diseases. Peptide-based GLP-1 drugs offer ...

Biogen Inc. (NASDAQ: BIIB) lost strength in Wednesday trading, after the Cambridge, Mass.-based company announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial.

Biogen made an acquisition offer to buy the remaining shares of SAGE that it did not already own for $7.22 per share in January. The offer price represented a premium of 30% on Sage Therapeutics ...